Search
Bovine type I collagen
go.drugbank.com/drugs/DB10771ApprovedInvestigationalExcellagen, a topical gel of bovine type I collagen, is used in the management of wounds including: partial and full- thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular … Interestingly, bovine type I collagen has been studied as a possible endovascular stent material, and has demonstrated promising results in rabbits [A32696].
Synonyms: Bovine type I collagen, Collagen Type I, BovineDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: TAFINLAR®75 MG CÁPSULAS DURAS, TAFINLAR® 50 MG CÁPSULAS DURASMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Categories: CCR5 Co-receptor Antagonist, Cytochrome P-450 SubstratesProducts: CELSENTRI® 150 MG, CELSENTRI® 300 MGBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRipasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.
Categories: Sympathomimetics in Glaucoma Therapy, Heterocyclic Compounds, 2-RingProducts: GLANATEC OPHTHALMIC SOLUTION 0.4% W/VMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.
Synonyms: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent sReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans
Dutogliptin
go.drugbank.com/drugs/DB11723InvestigationalDutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.
Categories: DPP-IV InhibitorsBenfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnBenfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. … The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.
Categories: Drugs Used in Diabetes